blinatumomab + glofitamab + teclistamab + talquetamab + epcoritamab + elranatamab

**Blinatumomab + glofitamab + teclistamab + talquetamab + epcoritamab + elranatamab** is a hypothetical combination regimen of six bispecific T-cell engager antibodies targeting B-cell antigens for potential use in hematologic malignancies. Blinatumomab (BiTE®, CD19/CD3) is FDA-approved for CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) across multiple lines including consolidation. The others—glofitamab (CD20/CD3), teclistamab and elranatamab (BCMA/CD3), epcoritamab (CD20/CD3), talquetamab (GPRC5D)—are approved or in late development primarily for relapsed/refractory multiple myeloma (RRMM) or non-Hodgkin lymphoma (NHL). This multi-TCE mix aims to engage T cells against diverse tumor antigens (CD19, CD20, BCMA, GPRC5D) to overcome resistance via antigen loss, though no clinical trials or approvals exist for this exact combination, posing risks of overlapping cytokine release syndrome, neurotoxicity, and B-cell aplasia.